Cspc Pharmaceutical Group Limited is an investment holding company whose subsidiaries focus on the research, development, and commercialization of pharmaceutical products. The group operates across key therapeutic areas including oncology, psychiatry, neurology, cardiovascular, immunology, respiratory, digestion and metabolism, and anti-infectives. Its R&D efforts are supported by eight core technology platforms, encompassing antibody-drug conjugates (ADC), messenger RNA (mRNA), small interfering RNA (siRNA), antibody/fusion proteins, cell therapy, and nano-formulation. Notable products include NBP, a Class 1 drug for stroke, Jinyouli, a long-acting white blood cell booster, and Mingfule, a thrombolytic drug for emergency stroke treatment. The group has out-licensed small molecule candidates targeting Lp(a) and MAT2A to international partners such as AstraZeneca and has advanced LNP/mRNA-based CAR-T therapies into clinical trials. It also develops long-acting agents like octreotide and semaglutide using an in situ gel platform and albumin nano-delivery technologies for drugs such as paclitaxel and docetaxel.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage cspc.com.hk
Sector Healthcare IR page cspc.com.hk/en/ir
Tags
oncology, neurology, cardiovascular, immunology, antibody-drug conjugates, mrna vaccines, cell therapy, nano-formulation, small interfering rna, stroke treatment, NBP, Jinyouli, Mingfule, Duoenyi, Anfulike, Duoenda, Oulaining, SYS6088
Press page —

Metrics

Valuation  
Market cap HK$ 95.63B
Market cap (USD) $ 12.187B
P/E 21.75
PEG —
P/BV 2.06
P/S 2.59
P/OCF 6.00
P/FCF 22.88
Dividend yield 4.0%
Turnover / mcap 1.1%
Returns  
ROE 11.3%
ROI 11.1%
ROIC 11.1%
Profit margin 14.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -13.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 1.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 26.006B 29.009B 31.45B 30.937B 27.867B 24.942B 22.103B 18.244B 13.196B 10.63B 9.267B 8.715B 7.858B 3.396B 6.076B 6.772B
Net profit 3.882B 4.328B 5.873B 6.091B 5.605B 5.16B 3.714B 3.171B 2.364B 1.805B 1.354B 1.009B 768.298M 1.771B 191.97M 654.761M
Free cash flow 3.551B 1.856B 2.286B 4.904B — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 7.95 4.19 5.94 7.92 6.87 7.11 12.42 9.8 1.23 — — — — — — —
Price performance 12m 0.94 -0.29 -0.29 0.1 0.04 -0.43 0.23 6.87 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Cspc Pharmaceutical Group Limited (ticker 1093), listed in Hong Kong.

Company History

Date Change Detail
Jun 30, 2019 Reporting currency Its HK reports are in CNY instead of HKD from this period. Earlier figures are shown in CNY, converted at each period end's exchange rate.

ETFs Holding Cspc Pharmaceutical Group Limited

ETF Weight in ETF Shares Market value As of
OZEM 4.61% 2,560,000 $ 2.574M Nov 17, 2026
EYLD 1.18% 9,223,793 $ 10.091M Jul 31, 2026
MEMA 1.00% 106,000 $ 124.94K Aug 31, 2026
AVES 0.62% 8,698,000 $ 8.921M Nov 16, 2026
AVSE 0.28% 582,000 $ 596.942K Nov 16, 2026
AVEM 0.27% 68,849,760 $ 70.617M Nov 16, 2026
DFEM 0.15% 12,842,000 $ 13.743M Nov 12, 2026
DEHP 0.14% 548,000 $ 586.446K Nov 12, 2026
DFSE 0.09% 512,000 $ 547.92K Nov 12, 2026
DFAE 0.08% 6,876,000 $ 7.358M Nov 12, 2026
NTSE 0.08% 50,000 $ 44.44K Jun 30, 2026
DFAX 0.06% 6,632,080 $ 7.097M Nov 12, 2026
DFEV 0.00% 96,000 $ 102.735K Nov 12, 2026